Last edition
News about "solid tumours"
The strategic collaboration between Biocytogen Pharmaceuticals Beijing and Moonlight Bio aims to combine antibody discovery and cell therapy expertise to develop innovative treatments for hard-to-treat cancers.
Solid Tumours. | 25/03/2026 | By News Bureau
IDEAYA Biosciences Enrolls First Patient in Phase I Trial of IDE892 for MTAP-Deleted Solid Tumours
IDEAYA Biosciences has initiated a Phase I clinical trial of IDE892, a PRMT5 inhibitor, for MTAP-deleted cancers including Non-Small Cell Lung Cancer and Pancreatic Cancer.
Solid Tumours | 11/03/2026 | By News Bureau | 155
HUTCHMED Starts Global Trial of HMPL-A580 for Solid Tumours
HUTCHMED has initiated a global clinical trial of HMPL-A580, a PI3K/PIKK-EGFR ATTC candidate, in patients with solid tumours. The study marks the second clinical programme from its next-generation ATTC platform, targeting both PAM pathway and EGFR signaling to enhance therapeutic synergy.
Solid Tumours | 06/03/2026 | By News Bureau
AstraZeneca Acquires Full Global Rights to AbelZeta's CAR-T Therapy C-CAR031 in USD 630 Million Deal
AstraZeneca has acquired AbelZeta Pharma’s China rights to CAR-T therapy C-CAR031 for up to USD 630 million, securing full global development and commercialisation rights for the liver cancer treatment.
Solid Tumours | 20/01/2026 | By News Bureau | 115
AstraZeneca Acquires Full Global Rights to AbelZeta's CAR-T Therapy C-CAR031 in USD 630 Million Deal
AstraZeneca has acquired AbelZeta Pharma’s China rights to CAR-T therapy C-CAR031 for up to USD 630 million, securing full global development and commercialisation rights for the liver cancer treatment.
Solid Tumours | 20/01/2026 | By News Bureau | 115
D3 Bio has received FDA IND clearance to initiate a Phase I trial of its KRAS G12D inhibitor D3S-003 and a Phase II combination study targeting KRAS G12C-mutant lung cancer.
Solid Tumours | 19/01/2026 | By News Bureau | 406
Rondo Therapeutics Begins First-in-Human Trial of Novel CD28 - Nectin-4 Bispecific for Solid Tumours
Rondo Therapeutics, a clinical-stage biopharmaceutical company developing next-generation T-cell engaging bispecific antibodies for solid tumours, has begun dosing patients in its phase 1/1b clinical trial of RNDO-564.
Solid Tumours | 07/12/2025 | By Darshana | 219
Imugene and JW Therapeutics have partnered to explore a new combination for refractory solid tumours, pairing Imugene’s onCARlytics (CF33-CD19) oncolytic virus with JW’s CD19 CAR-T therapy, Carteyva. The collaboration will begin with pre-clinical studies and advance to a Phase 1 investigator-initiated trial in China targeting hard-to-treat cancers.
Solid Tumours | 01/12/2025 | By Dineshwori | 170
SK Biopharmaceuticals Expands Radiopharma Portfolio with New WARF In-Licensing
SK Biopharmaceuticals has in-licensed a second radiopharmaceutical therapy candidate from the Wisconsin Alumni Research Foundation (WARF), further strengthening its pipeline and advancing its strategy to build an integrated, globally competitive radiotherapeutics portfolio.
Solid Tumours | 29/11/2025 | By Dineshwori | 209
Lupin to Present Phase 1 Data on LNP3693 (STING agonist) at ESMO Congress 2025
Lupin will present data from its Phase 1a clinical trial evaluating LNP3693, a STING agonist, at the ESMO Congress in Berlin, Germany, scheduled to be held from October 17 to October 21, 2025.
Solid Tumours | 13/10/2025 | By Dineshwori | 268
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy